Anixa Biosciences

About:

Anixa Biosciences develops and acquires patented technologies for the purposes of patent monetization and patent assertion.

Website: https://www.anixa.com/

Twitter/X: ituscorp

Top Investors: National Cancer Institute, U.S. Department of Defense

Description:

Anixa is a publicly-traded biotechnology company focused on harnessing the body's immune system in the fight against cancer. Anixa's therapeutic portfolio includes a cancer vaccine technology focused on the immunization against α-Lactalbumin to prevent triple negative breast cancer (TNBC), as well as a cancer immunotherapy program which uses a novel type of CAR-T, known as chimeric endocrine receptor T-cell (CER-T) technology. The company's diagnostic portfolio consists of Cchek™, a liquid biopsy technology for early detection of solid tumors based on the body's immune response to the presence of a malignancy. Anixa continually examines emerging technologies in complementary fields for further development and commercialization.